DAIICHI SANKYO Notice on Organizational Restructuring as of April 1, 2009

Tokyo, February 20, 2009 – Daiichi Sankyo Company, Limited has announced plans for organizational restructuring for its Group.

1. DAIICHI SANKYO COMPANY, LIMITED
   a) Corporate
      (i) Creation of the Corporate Finance & Accounting Department
          The Corporate Finance & Accounting Department will consolidate the Corporate Finance Department and the Corporate Accounting Department.

      (ii) Creation of the International Business Management Department
          The International Business Management Department will consolidate the International Business Department’s management function for group companies in Asia and Latin America and the current EU/US Business Management Department.

      (iii) Dissolution of the Human Resources Strategy Department
          The Human Resources Strategy Department will be dissolved. The Corporate Strategy Department and the Human Resources Department will take over its current functions.
(iv) Dissolution of the CSR Department
   The CSR Department will be dissolved. The departments in the Corporate will take over its current functions.

b) R&D Division

(i) Creation of the Translational Medicine & Clinical Pharmacology Department
   The Translational Medicine & Clinical Pharmacology Department will be created by consolidating the clinical research strategy function of each department in the R&D Division. The new department will be in charge of efficient evaluation of pharmacology and safety of products.

(ii) The Advanced Technology Research Laboratories to the Biologics Research Laboratories
   The Advanced Technology Research Laboratories will focus on the new specialization of antibody drug research and the new name will be Biologics Research Laboratories. Its current functions, development of informatics, analysis and others, are to be transferred to other departments within the R&D Division.

(iii) Reorganization of the roles of Clinical Development Department I, II, and III
   Current three Development Departments will be reorganized into two Departments. This reorganization aims to build more solid organization that allows for appropriate span-of-control, personnel training, and flexible resource allocation to respond to unexpected project changes.

(iv) Dissolution of the Pharmacology Research Laboratories
   The Pharmacology Research Laboratories will be dissolved. The departments within the R&D Division will take over its current functions.

(v) Dissolution of the R&D Information Management Department
   The R&D Information Management Department will be dissolved. Departments within the R&D Division will take over its functions.

(vi) Dissolution of the Development Management Department
   The Development Management Department will be dissolved. Departments within the R&D Division will take over its current functions.
2. DAIICHI SANKYO HEALTHCARE CO., LTD.

a) Sales Division

(i) Creation of the Sales Planning Department and the Sales Promotion Department

Both the Sales Planning Department and the Sales Promotion Department will be in charge of current functions of the Sales Administration Department.

(ii) Creation of the Chain Store Sales Department

The Chain Store Sales Department will be created to handle mass retail, grocery and general merchandise store sales channels.

(iii) Restructuring of branch offices

The following branches will be restructured to optimize span-of-control.

✓ The Tokyo Branch I and the Tokyo Branch II will be divided into the Tokyo Branch I, the Tokyo Branch II, the Yokohama Branch, the Kitakanto Branch, and the Omiya Branch.
✓ The Osaka Branch will be divided into the Kyoto Branch, the Osaka Branch I and the Osaka Branch II.

(iv) Dissolution of the Market Development Department

The various functions of the Market Development Department will be transferred within the Sales Division.

***